---
title: "Dongcheng Biochem: 225Ac-LNC1011 injection has received clinical trial approval"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/258486681.md"
description: "According to the Zhitong Finance APP, Dongcheng Biochem announced that its holding subsidiary Yantai LNC Biotechnology Co., Ltd. (referred to as \"LNC\") has received the clinical trial approval notice for the drug 225Ac-LNC1011 issued by the National Medical Products Administration of China, and will soon conduct clinical trials for prostate cancer"
datetime: "2025-09-23T09:21:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258486681.md)
  - [en](https://longbridge.com/en/news/258486681.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258486681.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/258486681.md) | [繁體中文](https://longbridge.com/zh-HK/news/258486681.md)


# Dongcheng Biochem: 225Ac-LNC1011 injection has received clinical trial approval

According to the Zhitong Finance APP, Dongcheng Biochem (002675.SZ) announced that its holding subsidiary Yantai LNC Biotechnology Co., Ltd. (referred to as "LNC") has received the clinical trial approval notice for the drug 225Ac-LNC1011 injection issued by the National Medical Products Administration of China, and will soon conduct clinical trials for prostate cancer

### 相关股票

- [Dongcheng Biochem (002675.CN)](https://longbridge.com/zh-CN/quote/002675.CN.md)

## 相关资讯与研究

- [Record Childhood Obesity Surge Puts MAHA Health Goals In Focus](https://longbridge.com/zh-CN/news/278540530.md)
- [Takeda-Backed Phase 3 Lung Cancer Trial Pits Novel IBI363 Against Docetaxel](https://longbridge.com/zh-CN/news/278423327.md)
- [Drag on oil supply could remain beyond Middle East conflict’s duration](https://longbridge.com/zh-CN/news/278322570.md)
- [11 immigrants died in US ICE detention between January and March 2026](https://longbridge.com/zh-CN/news/278516593.md)
- [The growing crisis of isolated seniors facing death without anyone by their side](https://longbridge.com/zh-CN/news/278415858.md)